Back to Research Home
ISRGIntuitive Surgical Inc
Health Care · Health Care Equipment · Large
$452.29+1.90%
As of 23 Oct 2026Mkt cap $131B
Stage 13
WAIT
Fundamentals
57.9/75
Technical
12.1/15
Independent
70.1/90
GCAE viewelevated earnings event risk blocks an independent BUY decision
Price
- 1M
- +13.2%
- 3M
- +26.8%
- 6M
- −6.2%
- 1Y
- −14.2%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 51.8xHist median 70.8x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 50.9x
- FCF yield
- 2.0%
Quality
- ROIC
- 17.4%
- Operating margin
- 28.1%
- FCF margin
- 24.7%
- Current ratio
- 4.9x
Growth
- Revenue growth
- +20.5%Latest FY YoY
- Revenue CAGR
- +15.2%
- EPS CAGR
- +14.0%
- FCF CAGR
- +9.2%
Capital
- Share-count trend
- +0.7%3Y annualised
- Net cash
- $3.2B-1.1x OCF
Annual trend
- CAGR 2021–2025
- +15.2%
- Latest · 2025
- $10B
- YoY
- +20.5%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- WATCH · RECHECK REQUIRED
Key takeaway
Procedure growth, installed-base expansion and recurring economics remain exceptional, but Medtronic's broadened Hugo/Cornerstone portfolio increases credible competitive intensity enough to keep valuation and multi-platform adoption under review.
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2027-01-21
- Price moved +22.5% since the last four-lens research baseline.
More details & evidence
Production decision
- Stage 13
- WAIT
- Technical state
- early-recovery
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded